NSG 533 EXAM 3 - WILKES
ADVANCED PHARMACOLOGY
(2026) ACTUAL QUESTIONS &
LATEST MOCK PRACTICE SET
169 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NSG 533 EXAM 3 - WILKES ADVANCED PHARMACOLOGY (2026) ACTUAL QUESTIONS & STUDY GUIDE |
GUARANTEE PASS. It contains 169 carefully selected questions that reflect the most current exam content and
testing strategies. Each question is accompanied by a correct answer and a detailed rationale that explains the
underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 169 Questions
Foundations - Application - NSG 533 3 Wilkes Advanced Pharmacology 2026 Actual & Study Guide
Guarantee PASS Advanced Pharmacology Clinical Therapeutics Prescribing AND Pharmacogenomics
Graduate Advanced Pharmacology FOR Nurse Practitioners
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Requires 1-43 Appropriate, Warfarin, Started, Diabetes, Chronic
Prescribed 44-86 Medication, Requires, Therapeutic, Likely, Index
Appropriate 87-129 Requires, Describes, Interaction, Medication, Opioid
Warfarin 130-169 Prescribed, Requires, Disease, Mechanism, Appropriate
TOTAL 169 All questions include answers and detailed rationales
,Section A - Requires
Q1.
A patient with treatment-resistant hypertension is being evaluated. Current regimen
includes lisinopril, amlodipine, and hydrochlorothiazide. Which additional agent would be
most appropriate to add, considering the mechanisms of action and potential for
synergistic blood pressure reduction?
A. Spironolactone B. Clonidine
C. Prazosin D. Aliskiren
Correct: A - Spironolactone
Rationale:Spironolactone is a mineralocorticoid receptor antagonist that is particularly
effective in resistant hypertension, often due to aldosterone breakthrough. Adding a fourth
agent from a different class (diuretic) is recommended by guidelines. Clonidine (central
alpha-agonist) and prazosin (alpha-1 blocker) are less favored as fourth-line. Aliskiren (renin
inhibitor) is not preferred due to adverse events when combined with ACE inhibitors/ARBs.
Q2.
A patient with type 2 diabetes and chronic kidney disease (eGFR 45 mL/min/1.73m²) is
inadequately controlled on metformin and insulin glargine. Which of the following agents
is most appropriate to add to improve glycemic control and provide cardiovascular
benefit?
A. Empagliflozin B. Sitagliptin
C. Glipizide D. Pioglitazone
Correct: A - Empagliflozin
Rationale:Empagliflozin, an SGLT2 inhibitor, is recommended for patients with T2DM and
CKD due to its cardiovascular and renal benefits, independent of glycemic control. It can be
used with eGFR >30. Sitagliptin is neutral but less beneficial; glipizide increases
hypoglycemia risk; pioglitazone may cause fluid retention and is less favorable in CKD.
Q3.
A patient on warfarin for atrial fibrillation is started on amiodarone for rhythm control.
What is the most appropriate management of warfarin therapy in this setting?
A. Immediately reduce warfarin dose by B. Maintain warfarin dose and check INR in
30-50% and monitor INR closely. one week.
Page 3
, Section A - Requires
C. Discontinue warfarin and switch to a D. Increase warfarin dose to compensate for
direct oral anticoagulant. potential interaction.
Correct: A - Immediately reduce warfarin dose by 30-50% and monitor INR closely.
Rationale:Amiodarone inhibits CYP2C9 and CYP3A4, decreasing warfarin metabolism,
leading to increased INR. To prevent bleeding, warfarin dose should be reduced by 30-50%
when starting amiodarone, with frequent INR monitoring. Maintaining the same dose risks
supratherapeutic INR; switching to DOAC may be an alternative but not the immediate
management.
Q4.
A patient with severe asthma is being initiated on omalizumab. Which of the following
parameters is essential to assess before starting therapy?
A. Baseline serum IgE level and body B. Forced expiratory volume in one second
weight (FEV1)
C. Blood eosinophil count D. Fractional exhaled nitric oxide (FeNO)
Correct: A - Baseline serum IgE level and body weight
Rationale:Omalizumab is a monoclonal antibody that binds to IgE; dosing is based on
baseline serum IgE and body weight. FEV1, eosinophils, and FeNO are important for
phenotyping and monitoring but are not used for dosing.
Q5.
A patient with major depressive disorder has failed adequate trials of two SSRIs and one
SNRI. Which of the following agents would be most appropriate to consider next, given its
unique mechanism of action?
A. Bupropion B. Mirtazapine
C. Tranylcypromine D. Esketamine
Correct: D - Esketamine
Rationale:For treatment-resistant depression, esketamine (NMDA antagonist) is
FDA-approved specifically for TRD, offering a novel mechanism. Bupropion and mirtazapine
are alternative antidepressants but not specifically for TRD. Tranylcypromine (MAOI) is
effective but requires dietary restrictions and is not first-line for TRD; esketamine has robust
evidence.
Q6.
A patient with a history of opioid use disorder is being considered for
buprenorphine/naloxone therapy. What is the primary reason for including naloxone in the
combination product?
Page 4
ADVANCED PHARMACOLOGY
(2026) ACTUAL QUESTIONS &
LATEST MOCK PRACTICE SET
169 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NSG 533 EXAM 3 - WILKES ADVANCED PHARMACOLOGY (2026) ACTUAL QUESTIONS & STUDY GUIDE |
GUARANTEE PASS. It contains 169 carefully selected questions that reflect the most current exam content and
testing strategies. Each question is accompanied by a correct answer and a detailed rationale that explains the
underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 169 Questions
Foundations - Application - NSG 533 3 Wilkes Advanced Pharmacology 2026 Actual & Study Guide
Guarantee PASS Advanced Pharmacology Clinical Therapeutics Prescribing AND Pharmacogenomics
Graduate Advanced Pharmacology FOR Nurse Practitioners
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Requires 1-43 Appropriate, Warfarin, Started, Diabetes, Chronic
Prescribed 44-86 Medication, Requires, Therapeutic, Likely, Index
Appropriate 87-129 Requires, Describes, Interaction, Medication, Opioid
Warfarin 130-169 Prescribed, Requires, Disease, Mechanism, Appropriate
TOTAL 169 All questions include answers and detailed rationales
,Section A - Requires
Q1.
A patient with treatment-resistant hypertension is being evaluated. Current regimen
includes lisinopril, amlodipine, and hydrochlorothiazide. Which additional agent would be
most appropriate to add, considering the mechanisms of action and potential for
synergistic blood pressure reduction?
A. Spironolactone B. Clonidine
C. Prazosin D. Aliskiren
Correct: A - Spironolactone
Rationale:Spironolactone is a mineralocorticoid receptor antagonist that is particularly
effective in resistant hypertension, often due to aldosterone breakthrough. Adding a fourth
agent from a different class (diuretic) is recommended by guidelines. Clonidine (central
alpha-agonist) and prazosin (alpha-1 blocker) are less favored as fourth-line. Aliskiren (renin
inhibitor) is not preferred due to adverse events when combined with ACE inhibitors/ARBs.
Q2.
A patient with type 2 diabetes and chronic kidney disease (eGFR 45 mL/min/1.73m²) is
inadequately controlled on metformin and insulin glargine. Which of the following agents
is most appropriate to add to improve glycemic control and provide cardiovascular
benefit?
A. Empagliflozin B. Sitagliptin
C. Glipizide D. Pioglitazone
Correct: A - Empagliflozin
Rationale:Empagliflozin, an SGLT2 inhibitor, is recommended for patients with T2DM and
CKD due to its cardiovascular and renal benefits, independent of glycemic control. It can be
used with eGFR >30. Sitagliptin is neutral but less beneficial; glipizide increases
hypoglycemia risk; pioglitazone may cause fluid retention and is less favorable in CKD.
Q3.
A patient on warfarin for atrial fibrillation is started on amiodarone for rhythm control.
What is the most appropriate management of warfarin therapy in this setting?
A. Immediately reduce warfarin dose by B. Maintain warfarin dose and check INR in
30-50% and monitor INR closely. one week.
Page 3
, Section A - Requires
C. Discontinue warfarin and switch to a D. Increase warfarin dose to compensate for
direct oral anticoagulant. potential interaction.
Correct: A - Immediately reduce warfarin dose by 30-50% and monitor INR closely.
Rationale:Amiodarone inhibits CYP2C9 and CYP3A4, decreasing warfarin metabolism,
leading to increased INR. To prevent bleeding, warfarin dose should be reduced by 30-50%
when starting amiodarone, with frequent INR monitoring. Maintaining the same dose risks
supratherapeutic INR; switching to DOAC may be an alternative but not the immediate
management.
Q4.
A patient with severe asthma is being initiated on omalizumab. Which of the following
parameters is essential to assess before starting therapy?
A. Baseline serum IgE level and body B. Forced expiratory volume in one second
weight (FEV1)
C. Blood eosinophil count D. Fractional exhaled nitric oxide (FeNO)
Correct: A - Baseline serum IgE level and body weight
Rationale:Omalizumab is a monoclonal antibody that binds to IgE; dosing is based on
baseline serum IgE and body weight. FEV1, eosinophils, and FeNO are important for
phenotyping and monitoring but are not used for dosing.
Q5.
A patient with major depressive disorder has failed adequate trials of two SSRIs and one
SNRI. Which of the following agents would be most appropriate to consider next, given its
unique mechanism of action?
A. Bupropion B. Mirtazapine
C. Tranylcypromine D. Esketamine
Correct: D - Esketamine
Rationale:For treatment-resistant depression, esketamine (NMDA antagonist) is
FDA-approved specifically for TRD, offering a novel mechanism. Bupropion and mirtazapine
are alternative antidepressants but not specifically for TRD. Tranylcypromine (MAOI) is
effective but requires dietary restrictions and is not first-line for TRD; esketamine has robust
evidence.
Q6.
A patient with a history of opioid use disorder is being considered for
buprenorphine/naloxone therapy. What is the primary reason for including naloxone in the
combination product?
Page 4
